LXEO

Lexeo Therapeutics, Inc. Common Stock

Healthcare
Biotechnology
$334M market cap

Forecast run · Sep 14, 2026Upside rank 439 of 3,136

Model Signal

ForecastQ Daily Probabilities

57.1%

36.3%

32.7%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$4.25

Price target$21.13

Implied move+397.2%

Analysts5

ForecastQ Portfolios

LXEO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.